Association of Plasma BDNF Levels with Different Stages of Alzheimer’s Disease: a Cross-Sectional Study

Ting Wang,Taoran Li,Shuwen Hao,Ying Han,Yanning Cai
DOI: https://doi.org/10.1080/01616412.2022.2129760
2022-01-01
Neurological Research
Abstract:BackgroundGrowing evidence shows that the expression of brain-derived neurotrophic factor (BDNF) is altered in the peripheral blood of participants with Alzheimer's disease (AD). It is unclear, however, whether altered BDNF expression is also observed in the early stages of AD.MethodsIn the present study, 138 normal controls (NC), 57 participants with subjective cognitive decline (SCD), and 37 participants with amnestic mild cognitive impairment (aMCI) and AD were included. Plasma BDNF protein levels were assessed using a commercial multiplex Luminex-based kit. Patient samples were also probed for the presence of BDNF gene variant rs6265.ResultsPairwise comparisons between the groups showed that there was not a significant difference in BDNF levels when comparing SCD with NC and when comparing SCD with aMCI/AD, but BDNF levels in aMCI/AD samples were increased when compared with NC samples. For models differentiating clinical groups, discriminant analysis was performed by including education, APOE genotype, and BDNF levels in the model. This approach distinguishes participants with SCD (AUC = 0.630) and aMCI/AD (AUC = 0.665) from NC.ConclusionOur results suggest that expression of BDNF in plasma is altered at the clinical stage of AD.
What problem does this paper attempt to address?